SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?


To: EagleRare who wrote (52181)8/21/2019 7:35:06 PM
From: JohnBeach  Read Replies (1) | Respond to of 57542
 
Right but when you go to the World Lung conference website and find presentation MA25.10 (Tuesday 9/10), it says "Abstract not Provided". Strangely, the other presentations have abstracts.



To: EagleRare who wrote (52181)8/22/2019 8:35:50 AM
From: TinfoilHat10 Recommendations

Recommended By
alwayshope
bnutman
bobbseytwins2001
CelebrityEquity
EMU2

and 5 more members

  Read Replies (2) | Respond to of 57542
 
To stem the tide by drawing from the ether circuits, the Daiichi data to me is a super positive.

Either we are given a chance to showcase our safety profile vs theirs, and thus a comparison of linker technologies - remember DS1062 had a couple stinkers in prelim data whereas IMMU 132 has been recognized by KOLs to be sufficiently safe to consider combos with PARP inhibitors. An investigator from Harvard started his own trial for heavens sake, that is a strong signal. At ESMO don’t look at efficacy, look at safety of DS1062 to compare with Sacituzumab Govitecan.

Or, the Daichi data is great and we get a boost from having comparable technology. I have seen this countless times in recent weeks.

My reading of the stock price tea leaves is this has been a technical drop to the 13.70 level area to test support, likely stoked by the FDA wildcard. However, Patient advocacy groups will be hellbent if IMMU132 doesn’t get approval at the next go.

Remember, Tecentriq for TNBC got approved in March in the US. Patients who have recently started will need an option soon, and more than 50% are not eligible for tecentriq given lack of PDL1 expression. Patients need options asap, we have one on the shelf. Btw, Gottlieb may have had his thumb on our last application, and he has now been replaced by a guy from the NCI. We are on the glide slope...

Final toke from the ether signals for today: I think doright is Goldenberg and Bobbsy is Bezhad. That’s at least who I picture when each posts, keep up the good work you two.